Ustekinumab market is expected to gain market growth in the forecast period of 2022-2029. Data Bridge Market Research analyses the market to account to grow at a CAGR of 5.90% in the above mentioned forecast period.
Ustekinumab is a human immunoglobulin (Ig) G1 kappa monoclonal antibody that targets the cytokines interleukin (IL)-12 and IL-23, which are implicated in immunological and inflammatory responses, respectively. 2 It was created by immunizing human Ig (hu-Ig) transgenic mice with recombinant human IL-12. It's a type of biologic disease-modifying anti-rheumatic medication (bDMARD) that’s employed to treat inflammatory diseases caused by the activation of the IL-12 and IL-23 signalling pathways. It works by preventing particular cells in the body from causing plaque psoriasis, Crohn's disease, psoriatic arthritis, and ulcerative colitis symptoms. Stelara is the brand name for the antibody Ustekinumab.
The rise in the prevalence of psoriasis patients globally is the major factor driving the market’s growth rate. Additionally, rising healthcare expenditure is the market driver influencing the growth rate of ustekinumab market. Furthermore, increasing geriatric population and upsurge in the number of clinical trial studies are the factors that will expand the ustekinumab market. Other factors including rise in the growing government initiatives and rising awareness will positively impact the market growth rate. Another significant factor that will cushion the growth of ustekinumab market is the increase in demand from various end-use industries. Also, rise in the level of disposable income and rapid urbanization will escalate the market growth rate for the mention forecast period mentioned above. Changing lifestyle and rising inclination towards smoking and alcohol consumption will drive the growth of ustekinumab market for the above mentioned forecast period.
Moreover, the rise in the research and development activities and emerging new markets will provide beneficial opportunities for the ustekinumab market in the forecast period of 2022-2029. Additionally, continuous economic development along with the improving healthcare infrastructure will act as major markets drivers that will create new opportunities for the markets growth rate.
However, high cost associated with product will impede the market’s growth rate. Also, side effects such as nausea, vomiting, dizziness, seizures, vision changes, confusion, itching, hives and difficulty in breathing, among others will hamper the ustekinumab market’s growth. Lack of awareness will further challenge the ustekinumab market in the forecast period mentioned above.
Browse a Detailed Summary of the Research Report @ https://www.databridgemarketresearch.com/reports/global-ustekinumab-market
Ustekinumab Market Scope and Market Size
The ustekinumab market is segmented on the basis of drug class, demographic, application, dosage form, end-users and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.
- On the basis of drug class, the ustekinumab market is segmented into interleukin inhibitors, and others.
- On the basis of demographic, the ustekinumab market is segmented into adult, and pediatric.
- On the basis of application, the ustekinumab market is segmented into arthritis, colitis, lupus erythematosus, myositis multiplex with palmoplantar pustulosis, cirrhosis of the liver, sarcoidosis, diabetes and others.
- On the basis of dosage form, the ustekinumab market is segmented into intravenous solution, and subcutaneous solution. The segment of intravenous solution is further sub-segmented into 5mg/ml. The segment of subcutaneous solution is further sub-segmented into 45 mg/0.5 mL and 90 mg/mL.
- On the basis of end-users, the ustekinumab market is segmented into clinic, hospital and others.
The ustekinumab market is also segmented on the basis of distribution channel into hospital pharmacy, retail pharmacy and online pharmacy.
Browse More Reports:
Global Maternal Health Market https://www.databridgemarketresearch.com/reports/global-maternal-health-market
Global Clinical Trials Market https://www.databridgemarketresearch.com/reports/global-clinical-trials-market
Global Dysphagia Market https://www.databridgemarketresearch.com/reports/global-dysphagia-market
Global Solid Tumors Market https://www.databridgemarketresearch.com/reports/global-solid-tumors-market
Global Lice Treatment Market https://www.databridgemarketresearch.com/reports/global-lice-treatment-market
Global Presbyopia Market https://www.databridgemarketresearch.com/reports/global-presbyopia-market
Global Physical Therapy Market https://www.databridgemarketresearch.com/reports/global-physical-therapy-market
Global Medical Display Market https://www.databridgemarketresearch.com/reports/global-medical-display-market
Global eHealth Market https://www.databridgemarketresearch.com/reports/global-ehealth-market
U.A.E Aesthetics/Cosmetics Market https://www.databridgemarketresearch.com/reports/uae-aesthetics-cosmetics-market
About Data Bridge Market Research:
An absolute way to forecast what future holds is to comprehend the trend today!
Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavours to provide appropriate solutions to the complex business challenges and initiates an effortless decisionmaking process. Data Bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune.
Contact Us:
Data Bridge Market Research
US: +1 888 387 2818
UK: +44 208 089 1725
Hong Kong: +852 8192 7475
Email: corporatesales@databridgemarketresearch.com
